Literature DB >> 16516157

Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease.

Ira L Goldknopf1, Essam A Sheta, Jennifer Bryson, Brian Folsom, Chris Wilson, Jeff Duty, Albert A Yen, Stanley H Appel.   

Abstract

We have used quantitative 2D gel electrophoresis to analyze serum proteins from 422 patients with neurodegenerative diseases and normal individuals in an unbiased approach to identify biomarkers. Differences in abnormal serum levels were found between amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and related disorders for 34 protein biomarker spots, nine of which were related to the complement system. Of these nine, four spots originated from the Complement C3b-alpha-chain (C3c(1), C3c(2a), C3c(2b), and C3dg). The C3c spots (C3c(1), C3c(2a), and C3c(2b)) had the same amino acid sequence and glycosylation, though only C3c(1) was phosphorylated. In addition, Complement Factors H, Bb, and Pre-Serum amyloid protein displayed different serum concentrations in ALS, PD, and normal sera, whereas Complement C4b gamma-chain and Complement Factor I did not. The differential expression of the complement proteins provides potentially useful biomarkers as well as evidence for the involvement of inflammatory processes in the pathogenesis of ALS and PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516157     DOI: 10.1016/j.bbrc.2006.02.051

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  43 in total

Review 1.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

Review 2.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 3.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

4.  C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice.

Authors:  Christian S Lobsiger; Severine Boillée; Christine Pozniak; Amir M Khan; Melissa McAlonis-Downes; Joseph W Lewcock; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

5.  Total protein is an effective loading control for cerebrospinal fluid western blots.

Authors:  Mahlon A Collins; Jiyan An; Danielle Peller; Robert Bowser
Journal:  J Neurosci Methods       Date:  2015-05-22       Impact factor: 2.390

Review 6.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients.

Authors:  E F Goodall; M S Haque; K E Morrison
Journal:  J Neurol       Date:  2008-07-18       Impact factor: 4.849

Review 8.  Application of "omics" to prion biomarker discovery.

Authors:  Rhiannon L C H Huzarewich; Christine G Siemens; Stephanie A Booth
Journal:  J Biomed Biotechnol       Date:  2010-03-04

Review 9.  The role of anti-inflammatory agents in Parkinson's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons.

Authors:  Christian S Lobsiger; Séverine Boillée; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.